| ALT Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the ALT shares outstanding history going back to 5/5/2017:
Also see: ALT Market Cap History ALT YTD Return |
ALT Shares Outstanding History — Altimmune Share Count Over Time
As of 8/7/2026 Altimmune has 194.52 million ALT shares outstanding. Investors often track the ALT shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows ALT share count trends over time, with 37 historical shares outstanding datapoints presented, dating back to 5/5/2017.
| ALT Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ALT Historical Shares Outstanding: +89.74% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ALT Stock Price Chart |
| About Altimmune Inc |
| Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Co. has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). Co. has completed the enrollment in its Phase II clinical trial of HepTcell. We show 37 historical shares outstanding datapoints in our coverage of ALT's shares outstanding history. Understanding the changing numbers of ALT shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ALT versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ALT by allowing them to research ALT shares outstanding history as well as any other stock in our coverage universe. |
| ALT Current Stock Quote |
Quotes delayed 20 minutes  Free ALT Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| ALT Share Performance |
| Shares Outstanding Peers |
| Altimmune (ALT) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
ALTS Shares Outstanding History ALUR Shares Outstanding History ALVR Shares Outstanding History ALXN Shares Outstanding History ALXO Shares Outstanding History ALZN Shares Outstanding History AMAG Shares Outstanding History AMAM Shares Outstanding History AMDA Shares Outstanding History AMED Shares Outstanding History More Healthcare companies » |
ALT Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
